Page 4,988«..1020..4,9874,9884,9894,990..5,0005,010..»

BioTime Announces Second Quarter 2013 Financial Results and Recent Corporate Accomplishments

Posted: Published on August 10th, 2013

ALAMEDA, Calif.--(BUSINESS WIRE)-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today reported financial results for the second quarter ended June 30, 2013 and highlighted recent corporate accomplishments. Second Quarter and Recent Corporate Accomplishments We are continuing to make progress towards our goal to become the leader in the field of regenerative medicine. We have the right team in place to capitalize on the opportunities in the field, and we will be one step closer to having the premier asset portfolio in regenerative medicine when our subsidiary Asterias Biotherapeutics, Inc. completes the acquisition of Gerons stem cell assets by the end of the third quarter this year, said Dr. Michael West, BioTimes Chief Executive Officer. We are also making continuing progress in developing our current revenues from Internet services and research product sales as well as in moving our near term diagnostic and therapeutic product opportunities toward clinical trials that are expected to begin later this year. In addition, we continued to raise capital to fund our efforts to provide adequate capital so that we can continue our work in this critical field of medicine. Financial Results Net Loss … Continue reading →

Posted in Stem Cell Human Trials | Comments Off on BioTime Announces Second Quarter 2013 Financial Results and Recent Corporate Accomplishments

$384,000 Stem Cell Burger Grown In a Lab! – Video

Posted: Published on August 10th, 2013

$384,000 Stem Cell Burger Grown In a Lab! Scientists have grown a stem cell burger in a laboratory, but what does this mean for science and global hunger? We look at the story with Lissette Padilla a... By: TheLipTV … Continue reading →

Comments Off on $384,000 Stem Cell Burger Grown In a Lab! – Video

Cerebral Palsy Stem Cell Treatment – Video

Posted: Published on August 10th, 2013

Cerebral Palsy Stem Cell Treatment Cerebral palsy is a heterogenous group of brain diseases producing chronic motor disability in brain during its active development. The ischemic damage to th... By: StemRx BioScience … Continue reading →

Comments Off on Cerebral Palsy Stem Cell Treatment – Video

Stem Cell Therapy Shows Promise in Repairing Brain Damage Even Hours After Stroke Occurs

Posted: Published on August 10th, 2013

Durham, NC (PRWEB) August 09, 2013 Stroke is a major health concern and is a leading cause of death in the United States, according to the Center for Disease Control. Despite significant research efforts, developing treatments that ensure complete recovery for stroke patients poses an extreme challenge, especially when more than a few hours have passed between onset of the stroke and administration of treatment. However, a new study released today in STEM CELLS Translational Medicine indicates that endothelial precursor cells, which are found in the bone marrow, umbilical cord blood, and as very rare cells in peripheral blood, could make a significant difference for these patients recovery even in the later stages of stroke. In animal studies, the treatment minimized the initial brain injury and helped repair the stroke damage. Previous studies indicated that stem/progenitor cells derived from human umbilical cord blood (hUCB) improved functional recovery in stroke models, noted Branislava Janic, Ph.D., a member of Henry Ford Health Systems Cellular and Molecular Imaging Laboratory in Detroit and lead author of the study. We wanted to examine the effect of hUCB-derived AC133+ endothelial progenitor cells (EPCs) on stroke development and resolution in rats. Dr. Janic and his team injected … Continue reading →

Comments Off on Stem Cell Therapy Shows Promise in Repairing Brain Damage Even Hours After Stroke Occurs

Stem Cell Therapeutics Acquires an Exclusive Option to License Prostate Cancer Stem Cell Assets

Posted: Published on August 10th, 2013

TORONTO, ONTARIO--(Marketwired - Aug 9, 2013) - Stem Cell Therapeutics Corp. (TSX VENTURE:SSS)(SCTPF), a biopharmaceutical company developing cancer stem cell-related therapeutics, today announced that it has entered into an option agreement to exclusively license worldwide rights to a series of prostate cancer stem cell assets from the University of York, United Kingdom. The assets originate from research funded by Yorkshire Cancer Research (YCR) and conducted in the YCR Cancer Research Unit, University of York, under the direction of Professor Norman Maitland. Stem Cell Therapeutics (SCT) intends to work closely with the Maitland group, leveraging its internal scientific strengths and its existing global network of collaborators. "This agreement provides Stem Cell Therapeutics with an opportunity to evaluate several highly promising therapeutic targets, all of which are expressed on prostate cancer stem cells, as well as on other types of cancers," added Dr. Bob Uger, SCT's Chief Scientific Officer. "Much of the York group's research is focused on hypothesis testing using powerful multicellular in vitro models and xenograft in vivo models of tumour development/metastasis. We will extend this research into the generation of monoclonal antibodies to these targets, with an ultimate goal of identifying new therapeutic development candidates." Dr. Maitland's research group … Continue reading →

Comments Off on Stem Cell Therapeutics Acquires an Exclusive Option to License Prostate Cancer Stem Cell Assets

House panel trains sights on unregulated stem-cell therapy in PH

Posted: Published on August 9th, 2013

By: InterAksyon.com August 9, 2013 10:02 AM InterAksyon.com The online news portal of TV5 MANILA, Philippines - The controversy over unregulated stem cell procedures in the country, including the role of unlicensed foreign doctors, has reached Congress, from where several alleged victims of malpractice came. The vice chairman of the House blue-ribbon panel is set to deliver a privileged speech Monday ahead of hearings on the current state of things in the stem cell therapy practice in the country, where experts warned earlier the "fad-like" atmosphere poses serious threat to public health and safety. Rep. Doy Leachon of Oriental Mindoro is expected to train his sights on, among others: the unethical practice of stem cell therapy without Food and Drug Administration (FDA) approval and on unapproved indications; the charging of exorbitant fees for still-experimental procedures; the criminal liabilities of doctors who prey on the miseries of desperate sick patients; a review of the potential conflict of interest, unethical conduct of self-promotion and violation of FDA rules in pushing stem cell therapy and charging of fees involving the Philippine Medical Association (PMA) and Philippine Society for Stem Cell Medicine (PSSCM). Leachon wants the academe, ethics experts and the Philippine College of … Continue reading →

Posted in Mesenchymal Stem Cells | Comments Off on House panel trains sights on unregulated stem-cell therapy in PH

Novel and alternative sources for cell replacement treatment of retinopathy

Posted: Published on August 9th, 2013

Public release date: 7-Aug-2013 [ | E-mail | Share ] Contact: Meng Zhao eic@nrren.org 86-138-049-98773 Neural Regeneration Research Damage or loss of photoreceptor cells is one of main culprits of visual impairment in many retinal degenerative diseases. Pharmacological treatment and surgical intervention are traditionally used to treat these retinal diseases, but they are not curative. It has been increasingly recognized that Wharton's jelly mesenchymal stem cells may differentiate into several cell lineages from all three germ layers. However, the capacity of Wharton's jelly mesenchymal stem cells to differentiate into retinal progenitor cells remains undetermined. A new study reported in the Neural Regeneration Research (Vol. 8, No. 19, 2013) used serum-free neural stem cell-conditioned medium or neural stem cell-conditioned medium supplemented with Dkk-1 and LeftyA to induce neural differentiation from Wharton's jelly mesenchymal stem cells. Inverted microscopy showed that after induction, the spindle-shaped or fibroblast-like Wharton's jelly mesenchymal stem cells changed into bulbous cells with numerous processes. Immunofluorescent cytochemical staining and reverse-transcription PCR showed positive expression of retinal progenitor cell markers, Pax6 and Rx, as well as weakly down-regulated nestin expression. These results demonstrate that Wharton's jelly mesenchymal stem cells are capable of differentiating into retinal progenitor cells in vitro, and … Continue reading →

Posted in Mesenchymal Stem Cells | Comments Off on Novel and alternative sources for cell replacement treatment of retinopathy

Additional US patent is important for the company, CEO says – Video

Posted: Published on August 9th, 2013

Additional US patent is important for the company, CEO says Glyn Edwards, CEO of drug discovery company Summit, tells Proactiveinvestors the additional patent for Duchenne Muscular Dystrophy treatment C1100 the compan... By: ProactiveInvestors … Continue reading →

Posted in Muscular Dystrophy Treatment | Comments Off on Additional US patent is important for the company, CEO says – Video

Sarepta Therapeutics Announces Second Quarter 2013 Financial Results and Recent Corporate Developments

Posted: Published on August 9th, 2013

CAMBRIDGE, MA--(Marketwired - Aug 8, 2013) - Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, today reported financial results for the three months and six months ended June 30, 2013, and provided an update of recent corporate developments. "We are excited that the FDA is open to an NDA filing for our drug eteplirsen for the treatment of Duchenne muscular dystrophy and the organization is focused on all of the activities necessary for a successful NDA submission in the first half of next year," said Chris Garabedian, president and chief executive officer of Sarepta Therapeutics. "The Sarepta team is planning for success as we continue activities related to our eteplirsen confirmatory study and our manufacturing scale up, while we begin pre-commercial activities to prepare for the potential approval of eteplirsen." Financial Results For the second quarter of 2013, Sarepta reported a Non-GAAP net loss of $14.6 million, or $0.46 per share, compared to a Non-GAAP net loss of $5.0 million for the second quarter of 2012, or $0.22 per share. The incremental loss is primarily the result of an $8.3 million decrease in government contract revenues as well as a $1.2 million increase in Non-GAAP operating expenses. … Continue reading →

Posted in Muscular Dystrophy Treatment | Comments Off on Sarepta Therapeutics Announces Second Quarter 2013 Financial Results and Recent Corporate Developments

Sarepta Therapeutics Announces Publication of Eteplirsen Clinical Study Results in the Annals of Neurology

Posted: Published on August 9th, 2013

Results Show a Significant Increase in Dystrophin Production and a Stabilization of Walking Ability in Duchenne Muscular Dystrophy Patients CAMBRIDGE, MA--(Marketwired - Aug 8, 2013) - Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, today announced the first peer-reviewed publication of the 48-week results from the Phase IIb clinical study of eteplirsen in the Annals of Neurology. Eteplirsen is an investigational medicine in development for the treatment of patients with Duchenne muscular dystrophy (DMD) who have a genotype amenable to skipping of exon 51. Published study results showed that once-weekly treatment with eteplirsen resulted in a statistically significant increase from baseline in novel dystrophin, the protein that is lacking in patients with DMD. In addition, eteplirsen-treated patients evaluable on the 6-minute walk test (6MWT) demonstrated stabilization in walking ability compared to a placebo/delayed-treatment cohort. Eteplirsen was well tolerated in the study with no clinically significant treatment-related adverse events. These data will form the basis of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for eteplirsen planned for the first half of 2014. "These unprecedented data for eteplirsen in DMD patients with genetic mutations correctable by skipping exon 51 represent a significant milestone … Continue reading →

Posted in Muscular Dystrophy Treatment | Comments Off on Sarepta Therapeutics Announces Publication of Eteplirsen Clinical Study Results in the Annals of Neurology

Page 4,988«..1020..4,9874,9884,9894,990..5,0005,010..»